Sandra J. Taler

Nov 12, 2023 | healio.com | Erik Swain |Richard Smith |George Bakris |Sandra J. Taler

You've successfully added Cardiology: Vascular Medicine to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Zilebesiran lowered systolic BP for 3 months, a reduction sustained at 6 months. Rates of major adverse events were low.